News Formal

These 10 medications are likely targets for Medicare price negotiations this fall

  • 📰 CNBC
  • ⏱ Reading Time:
  • 30 sec. here
  • 2 min. at publisher
  • 📊 Quality Score:
  • News: 15%
  • Publisher: 72%

Business Business Headlines News

Business Business Latest News,Business Business Headlines

It's still unclear which drugs Medicare will select, but several companies have revealed in court filings that four of their medications are targets.

Breo Ellipta, made byThe historic negotiations, established by the Inflation Reduction Act, are the cornerstone of the Biden administration's efforts to slash drug costs.

AARP is a powerful lobbying group that advocates on behalf of people ages 50 and older. The group strongly supports the MedicareThe list price of Januvia has surged 275% since 2006, according to the AARP. Eliquis has jumped 124% since 2012. Xarelto has increased 168% since 2011, and Imbruvica has risen 108% since 2013.

Merck booked $2.8 billion in revenue from Januvia in 2022. Bristol Myers Squibb generated $11.8 billion in sales from Eliquis last year. Johnson & Johnson reported $2.47 billion in revenue from Xarelto. And Abbvie posted $4.6 billion in sales of Imbruvica.

 

Thank you for your comment. Your comment will be published after being reviewed.
Please try again later.
We have summarized this news so that you can read it quickly. If you are interested in the news, you can read the full text here. Read more:

 /  🏆 12. in BUSİNESS

Business Business Latest News, Business Business Headlines

Similar News:You can also read news stories similar to this one that we have collected from other news sources.

AARP calls out the 25 most costly Medicare Part D drugs ahead of price negotiationsAARP is singling out the 25 most costly drugs under Medicare Part D plans as the government prepares to being negotiating prices with drug companies.
Source: dallasnews - 🏆 18. / 71 Read more »